CellREDM™ ECM & ADM Skin Booster: Composition and 160 mg Product Specifications
CellREDM™ is a manufacturer-described extracellular-matrix (ECM) product based on human allogenic acellular dermal matrix (ADM). AB LIFE GLOBAL provides this professional reference for clinics, distributors and technical buyers evaluating the product's supplied composition, specification and original brochure. This page presents manufacturer-supplied product information, not independent clinical verification.
What is CellREDM? ECM, collagen, elastin and GAGs
Extracellular matrix is the biological framework surrounding cells within connective tissues. The CellREDM English brochure describes an injectable/powder acellular dermal matrix containing collagen, elastin and glycosaminoglycans (GAGs). It is not presented as a hyaluronic-acid-only formulation. The brochure composition figure labels collagen 85%+, elastin 3.4%+, GAGs 0.9%+ and other ECM 10.7%+.
CellREDM 160 mg technical product profile
Product: CellREDM™; classification: Human allogenic tissue, acellular dermal matrix (injectable/powder).
Material components: collagen, elastin, GAGs and other dermal-matrix components.
Supplier-listed particle size: below 75 µm.
Pack quantity: 160 mg.
Pack contents: allogenic dermal collagen, one mixing syringe, two adapters and three needles.
Sterilization method: E-beam.
Storage: room temperature at 1–30°C.
Shelf life: 36 months from manufacture.
Precautions: single-use only; do not reuse or re-sterilize.
Manufacturer processing and material compatibility observations
The supplied material describes decellularization checks through H&E and DAPI staining. Its figures report residual dsDNA of 1,399.5 ng/mg in raw material compared with 0.09 ng/mg after processing. The accompanying in-vitro cytotoxicity comparison lists 85.70% cell viability for the processed graft. These values are laboratory observations reproduced from the manufacturer brochure, not a guarantee of clinical safety.
Brochure-reported four-week evaluation figures
The supplied clinical evaluation page reports changes from baseline at four weeks: skin texture +14.71%; skin tone +5.34%; dermal density +11.79%; elasticity +19.31%; and deep hydration +10.90%. The manufacturer also presents observations at one and two weeks. The scope, study conditions and suitability for an individual treatment require qualified professional assessment. The figures must not be read as guaranteed outcomes.
Professional use, packaging and documentation
The manufacturer's document discusses preparation materials such as normal saline, non-crosslinked hyaluronic acid and lidocaine. Exact preparation, administration and individual patient selection must follow the currently applicable approved instructions for use and professional clinical judgment. Manufacturer or tissue-bank registrations are distinct from authorization of a particular finished product in the destination market.
Compare CellREDM with other AB LIFE GLOBAL products
CellREDM is differentiated from the Si Belle PN + HA, peptide and PLLA products by its allogenic ADM/ECM-based material description. For buyers, the correct comparison includes material class, product presentation, packaging, approved intended use, sterility documentation and local market requirements.
Frequently asked questions
What is the CellREDM product format?
The source identifies an acellular dermal matrix product presented in a 160 mg injectable/powder format.
Does CellREDM contain only collagen?
No. The supplier lists collagen together with elastin, GAGs and other extracellular-matrix components.
What is the manufacturer's shelf life and storage condition?
The source indicates 36 months from the date of manufacture and 1–30°C room-temperature storage.
For a technical document request or a distribution enquiry, contact AB LIFE GLOBAL via the website. Product registration and market availability vary by destination market.
Comments